Age: | 0-80 |
Gender: |
Male
|
Healthy Volunteers: | No |
Keywords: | Hemophilia A, Inhibitors, Bleeding, Antibodies, WILATE, Factor VIII, Factor 8, Concentrate, Immune Tolerance, Immune Tolerance Induction |
Type: | Phase IV, double-blind randomized |
Target: |
120 Participants
|
Monthly evaluations (every other evaluation is in-person. Alternating evaluations may be over the phone)
Monthly lab tests
Daily infusion of WILATE® factor VIII concentrate from home for at least 6 months
Completion of a study diary for every bleeding event
Patients diagnosed with inherited Hemophilia A
Factor VIII activity ≤2%
History of high levels of inhibitors to Factor VIII
Locations |
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.